TheStreet Ratings

10 Best Biotech Stocks for 2016 - Top Stocks - TheStreet Ratings

Top Rated Stocks

Every day TheStreet Ratings produces a list of the top rated stocks, by industry. The following biotech stocks are rated highest by our value-focused model. This list will be updated as upgrades and downgrades occur.

Equity Top: Biotechnology



Source: TheStreet Ratings

Best Investments for

Biotechnology News

Nymox will not be successful in convincing the U.S. Food and Drug Administration (or its counterpart in Europe) to approve fexapotide to treat men with enlarged prostates.
8/26/16 2:23PM
An Amgen drug to treat secondary hyperparathyroidism was rejected by U.S. regulators Wednesday but the biotech company offered no public explanation for why the drug's marketing application was denied.
8/25/16 9:27AM
The Nasdaq Biotechnology Index fell 3.5% heading into Wednesday's close, with the loss triggered by a statement from Clinton's presidential campaign blasting Mylan for 'outrageous' pricing of the EpiPen.
8/24/16 3:44PM
Shares of biotech micro-cap Cyclacel Pharmaceuticals have doubled in price in the past 10 days. Call it the Lloyd Christmas effect.
8/22/16 12:36PM
Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.
8/22/16 7:07AM
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
8/12/16 7:01AM
The cancer immunotherapy company's cash position has plunged to the point where it may no longer be capable of paying its operating expenses.
8/11/16 10:41AM
A cancer immunotherapy shocker has Bristol-Myers Squibb tumbling and rival Merck soaring on Friday morning.
8/5/16 10:36AM
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
8/5/16 7:01AM
The big bounce in Biogen's valuation over the past month would likely bake in a good chunk of the upside premium that could come from any takeover offer.
8/3/16 7:01AM
The new deals signal a long-term commitment from two of the largest biotech companies to focus on cancer immunotherapy as a platform for future growth.
8/2/16 10:21AM
An experimental treatment for a rare, children's spine disorder developed by Ionis achieved the primary endpoint of a late-stage clinical trial, triggering Biogen to exercise a partnership option.
8/1/16 12:51PM
The negative study results from Seres are a setback for companies trying to harness the power of bacteria to treat diseases.
7/29/16 9:49AM
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
7/29/16 7:01AM
Celgene posted second-quarter earnings which exceeded analyst consensus expectations by a small margin but enough to raise guidance for the remainder of the year.
7/28/16 8:02AM